This suggests that PPARα ligands could be promising targets for combatting hepatic steatosis by repressing lipogenesis and hyperlipidaemia through increasing Insig2a gene expression, followed by the inhibition of SREBPs. The gene discussed is PPARA; the disease is Hepatic steatosis.